Information Provided By:
Fly News Breaks for December 3, 2018
DGX
Dec 3, 2018 | 07:11 EDT
BofA/Merrill analyst Derik de Bruin downgraded Quest Diagnostics to Neutral from Buy and reduced its price target to $93 from $98 following the cut in FY18 guidance. de Bruin does not believe the root causes for the weakness are well understood and fears there could be further reductions going forward.
News For DGX From the Last 2 Days
There are no results for your query DGX